Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Bladder Cancer
With an increasing number of treatment options for both non–muscle invasive bladder cancer (NMIBC) and advanced urothelial bladder cancer available, it is important for physicians to understand these various treatments and identify which option is likely to bring the greatest benefit to a specific patient.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Novel Treatments for Neuroendocrine Tumors
While there is a brand new treatment option for neuroendocrine tumors, it requires a wide array of practical guidance to be given safely and effectively.  Practitioners need to be well versed in patient eligibility, patient preparation for treatment, dosing, administration, and management of side effects.
Category
  • Neuroendocrine Tumors
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
BCOP Test - Novel Treatments for Neuroendocrine Tumors
To be eligible to take the BCOP test, you must first complete all credit requirements for the educational activity. The test is available for an additional fee of $49. Each activity is this series is worth 1 hour of BCOP credit.
Category
Format
Credits
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Central Nervous System Cancers
Histopathologic and molecular characterization of high-grade gliomas should now be standard practice, as specific markers used to define molecular subgroups among some anaplastic gliomas have been shown to have prognostic value. However, there are currently no targeted agents that have shown efficacy in the treatment of glioblastoma. The differential benefit from concurrent versus adjuvant temozolomide in patients with anaplastic gliomas continues to be unclear.
Category
  • Melanoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date December 18, 2020
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma
Since immune checkpoint inhibitors and BRAF targeted therapies are now available, there are many patients with advanced melanoma who are surviving multiple lines of treatment, so the complexity of cases is increasing.
Category
  • Melanoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date November 24, 2020
BCOP Test - Establishing a Place in Therapy for Biosimilars in Oncology
To be eligible to take the BCOP test, you must first complete all credit requirements for the educational activity. The test is available for an additional fee of $49. Each activity is this series is worth 1 hour of BCOP credit.
Category
Format
Credits
NCCN Pharmacy Updates: Establishing a Place in Therapy for Biosimilars in Oncology
Clinical oncology pharmacists have the opportunity to provide education on biosimilars and be a part of the multi-disciplinary decision-making process for incorporating biosimilars into practice sites. In addition, pharmacists will need training on reporting post-marketing surveillance data regarding immunogenicity, product variability and drift of biosimilars as use becomes widespread.
Category
  • Biosimilars
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date October 28, 2020
Optimizing Outpatient Care in Hematopoietic Cell Transplant Patients
Educating physicians and oncology nurses about the requirements and advantages of an outpatient HCT program would enable the implementation of this program in their institution and help identify appropriate patients who could benefit from this treatment approach.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Strategies to Reduce Clostridioides Difficile Infection in Hematologic Malignancies
A key component of managing patients with hematologic malignancies, especially those who are HCT recipients, lies in preventing, detecting, and treating C. diff infections by establishing C. diff screening procedures and the appropriate use of anti-infective therapy. Knowledge gained in this arena will support prevention, detection, and timely management of C. diff infections in patients with hematologic malignancies who are HCT recipients.
Category
  • Cancer-related Infections
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Management of Cardiac Complications in Hematologic Malignancies
Continued education for oncology care providers is necessary to promote awareness of the cardiac effects of hematologic malignancies and their treatment so that effective methods of management may be implemented.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation

Pages